Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech
An early-stage China biotech hopes to break into the GLP-1 race for obesity and diabetes as heavyweights dominate the field, with Novo Nordisk already …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
